CA2817846A1 - Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer - Google Patents

Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer Download PDF

Info

Publication number
CA2817846A1
CA2817846A1 CA2817846A CA2817846A CA2817846A1 CA 2817846 A1 CA2817846 A1 CA 2817846A1 CA 2817846 A CA2817846 A CA 2817846A CA 2817846 A CA2817846 A CA 2817846A CA 2817846 A1 CA2817846 A1 CA 2817846A1
Authority
CA
Canada
Prior art keywords
receptor antagonist
prolactin receptor
prolactin
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2817846A
Other languages
English (en)
French (fr)
Inventor
Wen Y. Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolix Inc
Original Assignee
Oncolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolix Inc filed Critical Oncolix Inc
Publication of CA2817846A1 publication Critical patent/CA2817846A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2817846A 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer Abandoned CA2817846A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/948,329 US8648046B2 (en) 2009-02-26 2010-11-17 Compositions and methods for visualizing and eliminating cancer stem cells
US12/948,329 2010-11-17
PCT/US2011/061040 WO2012068282A1 (en) 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer

Publications (1)

Publication Number Publication Date
CA2817846A1 true CA2817846A1 (en) 2012-05-24

Family

ID=45349276

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2817846A Abandoned CA2817846A1 (en) 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer

Country Status (9)

Country Link
US (2) US8648046B2 (enExample)
EP (1) EP2640412B1 (enExample)
JP (3) JP6306886B2 (enExample)
KR (1) KR20140009196A (enExample)
CN (2) CN106177915A (enExample)
AU (1) AU2011328935B2 (enExample)
CA (1) CA2817846A1 (enExample)
IL (1) IL226271A (enExample)
WO (1) WO2012068282A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167750A2 (en) * 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
WO2014105810A1 (en) 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
EP3707166A4 (en) * 2017-11-06 2021-11-24 Daniel J. Monticello CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN113956356B (zh) * 2021-10-27 2023-05-02 福州迈新生物技术开发有限公司 抗prl蛋白单克隆抗体、细胞系及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
CA2328520C (en) 1998-05-12 2013-06-25 Wen Y. Chen Use of anti-prolactin agents to treat proliferative conditions
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US7094750B2 (en) 2000-05-09 2006-08-22 Greenville Hospital System Therapeutic pore-forming peptides
AU2003230750A1 (en) * 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
RU2329274C2 (ru) 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
KR101162908B1 (ko) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
CN100479863C (zh) * 2006-09-06 2009-04-22 中国医学科学院北京协和医院 Cofilin 1与癌症的紫杉烷类化疗药物耐药性的相关性
JP2010513405A (ja) * 2006-12-21 2010-04-30 ノボ・ノルデイスク・エー／エス 二量体プロラクチンレセプターリガンド
US8420665B2 (en) * 2008-01-11 2013-04-16 Northwestern University Anti-cancer compounds
CN106177954A (zh) * 2009-02-26 2016-12-07 翁科里克斯公司 使癌干细胞可视化并消除癌干细胞的组合物和方法

Also Published As

Publication number Publication date
JP2013544254A (ja) 2013-12-12
IL226271A0 (en) 2013-07-31
JP2016029110A (ja) 2016-03-03
CN106177915A (zh) 2016-12-07
KR20140009196A (ko) 2014-01-22
AU2011328935B2 (en) 2016-08-11
JP6306886B2 (ja) 2018-04-04
WO2012068282A1 (en) 2012-05-24
JP2018062527A (ja) 2018-04-19
EP2640412A1 (en) 2013-09-25
US20110065639A1 (en) 2011-03-17
US20130231286A1 (en) 2013-09-05
AU2011328935A1 (en) 2013-05-30
IL226271A (en) 2017-05-29
EP2640412B1 (en) 2017-08-02
US8648046B2 (en) 2014-02-11
CN103298481A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
EP2640412B1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
CA2753804C (en) Compositions and methods for visualizing and eliminating cancer stem cells
TW200935055A (en) Peptides specific for hepatocellular carcinoma cells and applications thereof
CN114746094A (zh) 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法
US8754031B2 (en) Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
HK1231759A1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1189171A (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1231758A1 (en) Compositions and methods for visualizing and eliminating cancer stem cells
HK1166693A (en) Compositions and methods for visualizing and eliminating cancer stem cells
JP7254020B2 (ja) 融合遺伝子を含有するがんを治療する方法
AU2024252321A1 (en) Administration of a beta-catenin antagonist and methods of use
KR20240133687A (ko) 1차 요법으로 axl 유인 수용체를 이용한 국소 진행성 또는 전이성 췌장 선암종의 치료 방법
KR20200068272A (ko) PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
Lim et al. Biomarkers in GIST

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161115

FZDE Discontinued

Effective date: 20210222